Attached files

file filename
EX-32.1 - EXHIBIT 32.1 - Sorrento Therapeutics, Inc.exhibit321.htm
EX-31.2 - EXHIBIT 31.2 - Sorrento Therapeutics, Inc.exhibit312.htm
EX-31.1 - EXHIBIT 31.1 - Sorrento Therapeutics, Inc.exhibit311.htm
EX-10.2 - EXHIBIT 10.2 - Sorrento Therapeutics, Inc.exhibit102.htm
EX-10.1 - EXHIBIT 10.1 - Sorrento Therapeutics, Inc.exhibit101.htm
10-Q - 10-Q - Sorrento Therapeutics, Inc.srne3311810-q.htm
Exhibit 12.1
Sorrento Therapeutics, Inc.
Ratio of Earnings to Fixed Charges
(Dollars in thousands)

 
 
Three Months Ended
 
Fiscal Year Ended December, 31
(in $ thousands)
 
March 31, 2018
 
2017
2016
2015
2014
2013
 
 
 
 
 
 
 
 
 
Pretax Income (Loss) from Continuing Operations
 
(33,574)
 
15,315
(65,268)
(9,719)
(36,359)
(21,911)
Fixed Charges (per below)
 
1,904
 
5,201
1,712
1,651
1,628
254
Interests Capitalized
 
(1)
 
-
-
-
-
-
 
 
 
 
 
 
 
 
 
Earnings
 
(32,481)
 
20,516
(63,556)
(8,068)
(34,731)
(21,657)
 
 
 
 
 
 
 
 
 
Interests and Other Financial Charges
 
1,042
 
4,980
1,615
1,651
1,628
254
Interests Portion of Rental Expense
 
52
 
221
97
-
-
-
 
 
 
 
 
 
 
 
 
Fixed Charges
 
1,094
 
5,201
1,712
1,651
1,628
254
 
 
 
 
 
 
 
 
 
Ratio of Earnings to Fixed Charges
 
(29.7)
 
3.9
(37.1)
(4.9)
(21.3)
(85.3)